tiprankstipranks
Advertisement
Advertisement
Denali Therapeutics price target raised to $26 from $20 at Wedbush
PremiumThe FlyDenali Therapeutics price target raised to $26 from $20 at Wedbush
15d ago
Denali Therapeutics resumed with an Overweight at JPMorgan
Premium
The Fly
Denali Therapeutics resumed with an Overweight at JPMorgan
15d ago
Denali’s New Pompe Disease Trial Adds Depth to Its Rare Disease Pipeline
Premium
Company Announcements
Denali’s New Pompe Disease Trial Adds Depth to Its Rare Disease Pipeline
29d ago
Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley
PremiumThe FlyDenali Therapeutics price target lowered to $35 from $40 at Morgan Stanley
2M ago
Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank
Premium
The Fly
Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank
2M ago
Denali Therapeutics: Buy Rating Reiterated as TV Platform and Enzyme Portfolio Drive Long-Term Upside; $42 Price Target Maintained
Premium
Ratings
Denali Therapeutics: Buy Rating Reiterated as TV Platform and Enzyme Portfolio Drive Long-Term Upside; $42 Price Target Maintained
2M ago
Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
PremiumThe FlyBiogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
3M ago
Denali Therapeutics price target lowered to $40 from $42 at Morgan Stanley
Premium
The Fly
Denali Therapeutics price target lowered to $40 from $42 at Morgan Stanley
3M ago
Denali Therapeutics: AVLAYAH Momentum and Pipeline Progress Support Buy Rating, $39 Price Target Maintained
Premium
Ratings
Denali Therapeutics: AVLAYAH Momentum and Pipeline Progress Support Buy Rating, $39 Price Target Maintained
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100